Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of MT-7117 treatment in subjects with diffuse cutaneous systemic
sclerosis (dcSSc) using the American College of Rheumatology Composite Response Index in
Diffuse Systemic Sclerosis (ACR CRISS) at Week 52
Phase:
Phase 2
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Development America, Inc.